Pharmexa will start GV1001 liver cancer trial in third quarter

By Elaine Rigoli

Tampa, Fla., May 31 - Pharmexa said Wednesday that its application to begin the Heptovax phase 2 trial has now been submitted and the trial is planned to start in the third quarter of 2006.

The study, which will include up to 41 liver cancer patients, is a phase 2, open-label trial evaluating the safety and efficacy of GV1001 in advanced hepatocellular carcinoma.

The trial will enroll patients from three centers in Spain, France and Germany.

The application has been submitted in France and will be submitted in Spain shortly, according to a news release.

The primary endpoint of the trial is efficacy, measured by objective tumor response, the release said.

Secondary endpoints include the safety and immunogenecity of the vaccine.

Pharmexa is an international pharmaceutical company based in Copenhagen, Denmark.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.